Resistance to historically effective antimalarial drugs has contributed to the resurgence of malaria across sub-Saharan Africa in the past decade. The recent discovery of parasitic resistance to Artemisinin monotherapies underscores the urgent need for new and more effective antimalarial treatments.
Medicines for Malaria Venture (MMV) is a non-profit organization created to discover, develop and deliver new antimalarial drugs through effective public-private partnerships. MMV does this by providing drug companies with supplmental funding, technical expertise and logistical support. It currently has over 20 new products in the pipeline.
For more information about Drug Research for malaria control, please visit MMV's website.
November 22, 2015Bill Gates funds Australian malaria research
November 09, 2015Drug-resistant malaria parasite could spread to Africa
October 22, 2015Fake drugs threatening African lives: Congo pharmacists
October 02, 2015Study in Nigeria Finds 1 in 10 Malaria Drugs Are Poor Quality
June 01, 2015more
May 30, 2015The Global Pandemic of Falsified Medicines: Laboratory and Field Innovations and Policy Perspectives: Foreword
April 20, 2015Travel and fake artesunate: a risky business
September 22, 2012Anti-infective medicine quality: analysis of basic product quality by approval status and country of manufacture
July 16, 2012Implementation of basic quality control tests for malaria medicines in Amazon Basin countries: results for the 2005-2010 period
June 15, 2012more
June 24, 2008Scientists discover new compound that kills drug-resistant malaria
February 12, 2007MissionMore than 4.3 million medicines tested thanks to calculation grids
February 08, 2007Novartis Institute for Tropical Diseases Inaugurates New Indonesian Research Initiative to Study Dengue fever, Tuberculosis and Malaria
January 25, 2007more